General
Preferred name
TOZASERTIB
Synonyms
VX-680 ()
MK-045,MK-0457,VX-68 ()
VX-68, MK-045, Tozasertib Lactate, MK-0457, VX-680 ()
VX680 ()
MK-0457 ()
VX 680 ()
VX-680, MK-0457 ()
TOZASERTIB LACTATE ()
MK-045 ()
VX-68 ()
VX-680 LACTATE ()
MK0457 ()
P&D ID
PD003407
CAS
639089-54-6
899827-04-4
Tags
available
drug candidate
obsolete probe
Drug indication
Leukemia
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Tozasertib is a potent inhibitor of all three members of the Aurora kinase family .
(GtoPdb)
PRICE
29
DESCRIPTION
Tozasertib (VX 680; MK-0457) is an inhibitor of Aurora A/B/C kinases with Kis of 0.6, 18, 4.6 nM, respectively.
DESCRIPTION
inhibitor of aurora kinases
(Informer Set)
DESCRIPTION
Tozasertib (MK-0457) is a pan-Aurora kinase inhibitor (Kis: 0.6/18/4.6 nM for Aurora A/Aurora B/Aurora C). It shows selectivity against more than 190 different kinases.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
292
Organisms
2
Compound Sets
21
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Drugs
Clinical kinase drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugMAP
Enamine BioReference Compounds
Guide to Pharmacology
Informer Set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Obsolete Compounds
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Welcome Trust Cancer Drugs
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
45
Molecular Weight
464.21
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
3
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
3
cLogP
3.5
TPSA
102.07
Fraction CSP3
0.39
Chiral centers
0.0
Largest ring
6.0
QED
0.46
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Target
AURKA
AURKB
AURKC
AURKA, AURKB, AURKC, FLT3, ABL1, JAK2
AURKA, AURKB, AURKC, LCK
Aurora inhibitor
Aurora Kinase,Autophagy,Bcr-Abl,FLT3
Aurora A
Aurora B
Aurora C
Compound status
clinical
Pathway
mitosis
Autophagy
Cell Cycle/Checkpoint
Chromatin/Epigenetic
Cell Cycle/DNA Damage
Epigenetics
MOA
Aurora Kinase
Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor
Therapeutic Class
Anticancer Agents
Source data
